Genmab — Oktober 2025
-
Good move by Genmab to proceed this fast with the tender offer, confirming they have no doubts about their offer. After all, very theoretically, Genmab could decide NOT to pursue the transaction if they felt they had done something really really stupid. It would cost them over $400 million in termination fees -and their reputation- but in theory i guess it is possible...
-
And we should not forget that Genmab was not the only bidder; there was (at least) 1 party interested in partnering Peto, and there were (at least?) 2 parties bidding at a price very close to the $97 Genmab ended up paying... and these had done the same due diligence
-
tisotumab isn't the only ADC with toxicity challenges https://x.com/Dr_Oncologista/status/1980617077204390285/photo/2
-
Det lader til at kursen er stabiliseret på det amerikanske marked. Lad os se om der fortsat sælges ud i morgen. Eller om turen skal op igen
-
Ny i Genmab - købte i går i kurs 1886.
-
Sikker trættende spørgsmål: Aktiesplit
-
Er det i spil?
-
@tudekiksen. Nok ikke i Genmab.
-
@bibob Tak for svar. Kunne jo være man ville splitte 1 til 10... Men det er altså ikke på tale...
-
In a report released yesterday, Michael Schmidt from Guggenheim reiterated a
Buy rating on Genmab, with a price target of $45.00 https://www.theglobeandmail.com/investing/markets/stocks/GMAB-Q/pressreleases/35581001/guggenheim-sticks-to-their-buy-rating-for-genmab-gmab/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind